Demoly Pascal, Dreyfus Isabelle, Dhivert-Donnadieu Henriette, Mesbah Kamal
Allergy Department, INSERM U657, Maladies Respiratoires, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.
Ann Allergy Asthma Immunol. 2009 Sep;103(3):260-6. doi: 10.1016/S1081-1206(10)60191-3.
Few studies have been conducted to assess treatment options for patients with sensitivities to cypress pollens, important triggers of allergic rhinitis (AR) in the Mediterranean region.
To evaluate the effect of desloratadine, a second-generation antihistamine, on AR symptoms caused by cypress pollens native to France.
Adults (N=233) with symptomatic cypress pollen allergies were randomized to receive desloratadine, 5 mg, or placebo daily for 15 days during 2 consecutive cypress pollen seasons. The primary end point was the percentage change from baseline in morning total nasal symptom scores on day 14; secondary assessments included total symptom score, peak nasal inspiratory flow, the Rhinoconjunctivitis Quality of Life Questionnaire, and global response to therapy.
On day 14, the desloratadine group had a significantly greater percentage decrease in total nasal symptom score vs the placebo group (-40% vs. -30%; P < .04). Similarly, on day 14, there was a 47% and 37% respective decrease in total symptom score (P = .01). Mean peak nasal inspiratory flow scores showed numeric, albeit not statistically significant, improvements from baseline through day 14 with desloratadine. A significantly greater improvement in Rhinoconjunctivitis Quality of Life Questionnaire scores occurred with desloratadine vs placebo on day 14 (-1.4 vs. -0.9; P = .004). The mean global response to therapy was better with desloratadine vs placebo (3.4 vs. 3.9; P = .004). The adverse event rate was similar in both groups.
Desloratadine is efficacious and safe for the treatment of AR induced by cypress pollens; it also improved disease-related quality of life.
针对地中海地区过敏性鼻炎（AR）的重要诱因——柏树花粉过敏患者的治疗方案，相关研究较少。
评估第二代抗组胺药地氯雷他定对法国本土柏树花粉引起的AR症状的疗效。
233名有症状的柏树花粉过敏成人患者，在连续两个柏树花粉季节中，随机分组，每日分别服用5毫克地氯雷他定或安慰剂，持续15天。主要终点是第14天早晨总鼻症状评分较基线的变化百分比；次要评估指标包括总症状评分、鼻吸气峰流速、鼻结膜炎生活质量问卷以及对治疗的总体反应。
在第14天，地氯雷他定组总鼻症状评分较安慰剂组有显著更大幅度的下降（-40%对-30%；P <.04）。同样，在第14天，总症状评分分别下降了47%和37%（P =.01）。从基线到第14天，地氯雷他定组的平均鼻吸气峰流速评分虽无统计学显著改善，但有数值上的提高。在第14天，地氯雷他定组的鼻结膜炎生活质量问卷评分较安慰剂组有显著更大改善（-1.4对-0.9；P =.ooo4）。地氯雷他定组对治疗的总体平均反应优于安慰剂组（3.4对3.9；P =.004）。两组不良事件发生率相似。
地氯雷他定治疗柏树花粉诱发的AR有效且安全；还改善了疾病相关的生活质量。
